Iceland

Reimbursed Care Access

Iceland maintains a restrictive national narcotics law that explicitly lists many classic psychedelic compounds as controlled substances; medical access is limited to approved pharmaceutical products and authorised clinical research, while investigational or off-label psychedelic psychotherapy remains nascent and largely confined to research or private arrangements. The only psychedelic-derived product with a formal EU marketing authorisation that is relevant to Iceland is esketamine (Spravato); other compounds (psilocybin, MDMA, DMT, mescaline, ibogaine, etc.) are expressly controlled under Icelandic law and have no routine public reimbursement or general clinical availability outside approved trials or narrow ministerial exemptions.